Canaccord Genuity Maintains Buy on Biohaven, Raises Price Target to $32

Benzinga · 10/31 00:30
Canaccord Genuity analyst Sumant Kulkarni maintains Biohaven (NYSE:BHVN) with a Buy and raises the price target from $21 to $32.